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cantly decreased with caspase inhibition in both treated groups,Effects of caspase inhibition on the progression of experimental
but not serum creatinine level.glomerulonephritis.
Conclusion. This study clearly indicates that caspase inhibi-Background. Caspase-3 has a central role in the execution
tion reduces renal apoptosis, ameliorates inflammation andof apoptosis. In a nephrotoxic nephritis (NTN) model, we pre-
fibrosis, and improves proteinuria in experimental glomerulo-viously demonstrated an up-regulation of caspase-3 that was
nephritis, which may mainly be related to changes in the cas-associated with inappropriate renal apoptosis, inflammation,
pase enzymatic system.tubular atrophy, and renal scarring.
Methods. We applied a pan caspase inhibitor, Boc-Asp
(OMe)-fluoro-methyl-ketone (B-D-FMK), directly to rat NTN
kidney using an intrarenal cannula fed from an osmotic pump. Chronic glomerulonephritis remains one of the mostAnimals were treated either for the first 7 days (acutely) to
common causes of chronic renal failure (CRF) world-determine the effects on renal inflammation (ED-1 staining)
wide. Progressive glomerulonephritis is associated withand apoptosis (in situ end labeling of fragmented DNA), or
for 28 days commencing 15 days after NTN (chronically) to initial inflammatory changes followed by glomeruloscle-
observe the effects on cell death and renal fibrosis. Changes of rosis, tubular atrophy, and interstitial fibrosis [1]. Apo-
caspase-3 and caspase-1 activity were detected by fluorometric ptosis, a morphologic form of programmed cell death,
substrate cleavage assay. Changes in caspase-3 and caspase-1,
has a dual role in renal injury. On one hand, it may serveinterleukin-1 (IL-1), and collagen I, III, and IV proteins
as a healing mechanism related to the resolution of in-and mRNA were detected by Western blotting and Northern
blotting, respectively. flammation [2, 3], while on the other hand, inappropriate
Results. In both treated groups, caspase-3 activity was inhib- apoptosis causes cell deletion that affects renal function
ited, and 17 and 24 kD active caspase-3 proteins were reduced and remodeling [4–7]. Therefore, the control of apopto-
significantly. A compensatory increase of caspase-3 mRNA oc-
sis and its mediators could be a potential target for thera-curred in the acutely treated group, but decreased in the chroni-
peutic interventions manipulating both the early inflam-cally treated group (P  0.05). Although there were no signifi-
mation as well as the late atrophic and fibrotic changescant changes in caspase-1 activity and its active protein, the
observed decrease in its precursor in the chronic group was in progressive glomerulonephritis.
increased by treatment (P  0.05). Further, IL-1 precursor Although different signals initiate apoptosis, the phe-
and its mRNA were significantly reduced by treatment only notype of apoptosis is surprisingly similar even in differ-in the chronically treated group. Apoptosis was decreased in
ent cell types, suggesting that the final stage of apoptoticthe glomeruli of acutely treated rats, and in the tubules and
death is highly conserved [8]. A class of cysteine prote-interstitium of chronically treated animals (P 0.05). Glomer-
ular inflammation was decreased only in the acutely treated ases (caspase family, 14 different members) coordinates
group, whereas tubulointerstitial inflammation was lowered in the execution of the death program. In particular, cas-
both treated groups (P  0.05). Glomerulosclerosis was re- pase-3 is a major execution enzyme acting upstream of
duced in both inhibitor groups, with a reduction in tubulointer-
DNA fragmentation [9–11]. All proforms of caspase con-stitial fibrosis and collagen I, III, and IV mRNA restricted to
tain both recognition and cleavage sites implying thatchronically treated animals (P  0.05). Proteinuria was signifi-
activation of caspase occurs either autocatalytically or
by other caspase. Two major pathways of caspase-3 acti-
Key words: B-D-FMK, caspase-3, apoptosis, inflammation, fibrosis. vation exist, either mediated by death receptors (through
caspase-8) or by mitochondria (through caspase-9) [10].Received for publication April 25, 2002
Recently, it was also reported that caspase could beand in revised form October 4, 2002, and December 9, 2002
Accepted for publication January 14, 2003 activated via an endoplasmic reticulum (ER) pathway
(through caspase-12) [12]. 2003 by the International Society of Nephrology
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Apart from the promotion of apoptotic cell death, during the course of experimental GN. We observed a
significantly protective effect by the inhibition of caspasethe caspase family of enzymes also participates in the
processing of proinflammatory cytokines [13, 14]. Cas- enzymatic pathway on renal cell apoptosis, inflammation
and fibrosis, while also partially improving functionalpase-1 [interleukin (IL)-1–converting enzyme (ICE)] is
the pro-IL-1 processing enzyme [15]. IL-1, a cytokine parameter.
with a wide range of proinflammatory actions, is in-
creased in the kidneys of rat antiglomerular basement
METHODS
membrane (GBM)–mediated glomerulonephritis [neph-
Nephrotoxic serum nephritisrotoxic nephritis (NTN)] and plays an important role
in crescent formation and tubulointerstitial injury [16]. Glomerulonephritis was induced in male Wistar Kyoto
rats weighing 200 to 300 g with a single injection of 0.5Early and late treatment with an IL-1 receptor antagonist
prevents and suppresses the progression of crescentic mL of rabbit antirat GBM serum into the tail vein [7].
B-D-FMK (316.5 g/24 hours) (Enzyme Systems Prod-glomerulonephritis in this model [17, 18]. Caspase-1
knockout mice treated with lipopolysaccharide have a ucts, Livermore, CA, USA) or drug vehicle [dimethyl
sulfoxide (DMSO)] (Sigma, Dorset, UK) was adminis-blunted IL-1 response [15] and demonstrate reduced
ischemic brain injury [19]. tered by intrarenal delivery [30] using a fenestrated can-
nula attached to subcutaneous Alzert osmotic mini-Caspase inhibitors, including peptide-based inhibitors
of caspase, are highly effective in preventing apoptotic pump (Charles River Ltd., Kent, UK). The dose of B-D-
FMK was calculated on the basis that it appears to be thecell death in in vitro models of apoptosis [20, 21]. The
investigation of caspase-3–deficient mice has suggested that minimum dose required for maximum caspase inhibitory
effect in renal cell culture (Abstract; Yang et al, J Amthis enzyme may be an appropriate target for therapeutic
interventions in diseases resulting from inappropriate Soc Nephrol 11:A2468, 2000) and the significant effect
observed in a pilot in vivo study as well as the order ofapoptosis [22]. For example, the elevated apoptosis in
hepatic parenchymal cells induced by tumor necrosis magnitude of other drugs administered by this method
in our laboratory [30]. B-D-FMK or DMSO was adminis-factor- (TNF-)–mediated endotoxemia was prevented
by benzyloxycarbonyl-Val-Ala-Asp (OMe) (ZVAD), tered to rats on two time schedules. The first started one
day before the induction of NTN and continued for 7providing a caspase-3 inhibition, which reduced the se-
verity of the disease [23]. In addition, the administration days (acutely). The second started 15 days after NTN
and continued for 28 days (chronically). The acutelyof Boc-Asp (OMe)-fluoro-methyl-ketone (B-D-FMK)
after cerebral hypoxia/ischemia, inhibited caspase-3 ac- treated group was designed to observe the effects on
caspase-3 inhibition on the inflammatory reaction whiletivity and was neuroprotective [24]. More recently, it has
been reported that ZVAD-FMK reduced the caspase-3 the chronically treated group was intended to allow the
evaluation of chronic scarring phase. Rats were injectedactivity and prevented the early onset of not only renal
apoptosis, but also inflammation and tissue injury in a with normal rabbit serum and received DMSO as con-
trols for both time points (each experimental group con-mouse model of renal ischemia/reperfusion [25].
Previous studies have demonstrated the increase of cas- sisted of six to eight rats). Rats were killed at the end
of the experiment. Kidneys were removed and quartered.pase-3 in various experimental models of renal disease,
including ischemic renal injury [26] and cyclosporin One quarter was fixed in 10% (wt/vol) neutral buffered
formalin and another in 2.5% (vol/vol) glutaraldehydeA–induced nephrotoxicity [27]. Our work has high-
lighted the importance of apoptosis in the development for histologic, immunohistochemical, and electron mi-
croscopic examination. The remaining tissue was snap-of glomerulosclerosis and tubular atrophy [28], where
up-regulation of caspase-3 activity, protein, and synthesis frozen and stored in liquid nitrogen for activity, protein,
and mRNA analyses. Serum creatinine (standard auto-has been described in both the subtotal nephrectomy
(SNx) [7] and NTN [29] models of experimental renal analyser techniques) and 24-hour urinary protein (Lowry
method) were measured at sacrifice. Rats were housedscarring. Given these findings, a similar blockade of cas-
pase-3 in progressive renal scarring may provide a novel at constant temperature and humidity on a 12-hour light/
dark cycle and fed ad libitum on standard rat chow. Allmeans to the treatment of renal scarring by controlling
inappropriate apoptosis. Therefore, in this study, we procedures were carried out according to the regulations
laid down by the Home Office (Animal Scientific Proce-have applied a cell-permeable pan caspase inhibitor,
B-D-FMK, to rats with progressive NTN in order to dure Act 1986, UK).
block the activity of caspases (predominantly caspase-3,
Detection of tissue caspase-3 and caspase-1 activitybut also significantly caspases 1, 8, 9, and 12) and subse-
quent apoptotic cell death. We have determined the ef- Caspase-3 or caspase-1 activity was detected by the
modified Fluorometric CaspACETM Assay System (Pro-fects of caspase inhibition on the early inflammatory/apo-
ptotic changes and the late apoptotic/sclerotic changes mega, Southampton, UK) using 100 g of protein ex-
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tracted from renal tissue [7]. This assay is based on the sodium phosphate and 7% (wt/vol) sodium dodecyl sul-
fate (SDS)] at 65C [7, 36]. The filter was exposed toability of caspase-3 or 1 to cleave the fluorogenic sub-
strate of either Ac-DEVD-amino-4-methyl coumarin Kodak Biomax MS film (Sigma) for 24 to 48 hours.
Autoradiographs were semiquantitatively analyzed by(AMC) or Ac-YVAD-AMC. The specificity of the assay
was determined using the caspase-3 or 1 inhibitor Ac- scanning volume density using a Bio-Rad GS-690 densi-
tometer and Molecular Analyst version 4 software. Vol-DEVD-CHO or Ac-YVAD-CHO. The proteolytic cleav-
age of substrates was monitored in a fluorescence mi- ume density was corrected for loading using the house-
keeping gene cyclophilin [7], which remained stablecroplate reader (SOFTmax PRO, Molecular Devices
Corp., Sunnyvale, CA). The fluorescence intensity was during the experiment. Results were expressed as the
percentage of the average controls’ mRNA volume den-calibrated with standard concentrations of AMC and
caspase-3 or caspase-1 activity was expressed as pmol sities. Transcript size was determined by comparison to
RNA molecular weight markers (Promega) using theAMC liberated per minute per g protein at 30C.
same analysis package and by visual comparison to the
Measurement of tissue caspase-3, caspase-1, and IL-1 ribosomal RNA subunits.
protein by Western blot
In situ end labeling (ISEL) of apoptotic cellsTwenty g of protein [20% (wt/vol) homogenate] was
separated on a 15% (wt/vol) polyacrylamide denaturing Using paraffin sections, fragmented nuclear DNA as-
sociated with apoptosis was labeled in situ with digoxi-gel and electro-blotted onto Hybond-C membrane (Amer-
sham Life Science, Buckinghamshire, UK). This was genin-deoxyuridine (dUTP) by terminal deoxynucleotidyl
transferase (TdT) using the ApopTag Plus peroxidaseblocked with 3% (wt/vol) bovine serum albumin (BSA)
and probed with a polyclonal rabbit antirat full-length kit (Appligene Oncor, Illkirch, France) [28, 37]. For each
experimental animal, more than 30 glomerular cross-caspase-3 (Santa Cruz Biochemicals, Santa Cruz, CA,
USA), caspase-1 (Upstate Biotechnology, Milton Keynes, sections and 20 high-power (400 magnification) fields
of tubulointerstitium were examined blinded to the ex-UK), and IL-1 (NIBSC, Potters Bar, UK) antibodies
at 1:1,000, 1:500, and 1:1000 dilution, respectively. The perimental code by two of the authors (B. Yang and
A.M. El Nahas). In situ end labeling (ISEL)  nucleiantibody binding was revealed using an antirabbit perox-
idase conjugate (Dako, Glostrup, Denmark) or the ABC per glomerulus, per 400 tubular cells, and per interstitial
field were determined, respectively. To substantiate theElite Kit (Vector Laboratories, Peterborough, UK) di-
luted at 1:1,000 and the ECL chemiluminescent detection specificity of our results, we confirmed apoptosis by light
and electron microscopy to evaluate the morphologicsystem (Amersham Life Science). Developed films were
semiquantitatively analyzed by scanning volume density features; only strongly positive ISEL cells with observ-
able morphologic features of apoptosis such as shrunkenusing a Bio-Rad GS-690 densitometer and Molecular
Analyst version 4 software (Bio-Rad Laboratories, Ltd., cells with condensed nuclei were counted [38, 39].
Herts, UK). Results were expressed as the percentage of
Evaluation of inflammation by ED-1 immunostainingthe average controls’ mRNA volume densities. Transla-
tion size was determined by comparison to protein mo- Cellular inflammation was evaluated by ED-1 (a spe-
cific rat monocyte/macrophage marker) immunostaininglecular weight markers (Bio-Rad Laboratories, Ltd.) us-
ing the same analysis package. on paraffin sections using a standard avidin-biotin perox-
idase complex technique [40]. The sections were pre-
Northern blot analysis of caspase-3, IL-1, collagen I, treated with 0.125% (wt/vol) trypsin and incubated with
III, and IV mRNA the primary antibody (monoclonal mouse antirat ED-1
antibody, Serotec Ltd., Oxford, UK) at 1:50 dilution orFifteen g of total RNA extracted using TRIzol re-
agent (Life Technologies BRL, Paisley, UK) were elec- normal mouse immunoglobulin G (IgG) at the same
protein concentration of primary antibody as negativetrophoresed on a 1% (wt/vol) agarose/3-(N-Morpholino)
propanesulfonic acid (MOPS)/formaldehyde gel, capil- control. The antibody binding was revealed using the
ABC Elite Kit (Vector Laboratories, Peterborough,lary blotted onto Hybond-N membrane (Amersham Life
Science) and crosslinked with 70 mJ/cm2 radiation (UV UK) and 3-amino-9-ethylcarbazole substrate. ED-1
cells in glomeruli and interstitium were semiquantita-Crosslinker, Amersham Life Science) [31]. This was then
probed with 32P-labeled deoxycytidimine triphosphate tively assessed by the same counting system as described
above for ISEL.(dCTP) random primed DNA probes. Specific random
primed DNA probes were constructed from the follow-
Estimation of renal scarringing sequences: rat caspase-3 [26], IL-1 [32], human col-
lagen 1 (I) [33], rat collagen 1 (III) [34] and human The extent of renal scarring was semi-quantitatively
analyzed on Masson’s Trichrome (MT)–stained sectionscollagen1 (IV) [35]. Prehybridization and hybridization
were performed using the Church buffer system [0.5 mol/L at 200 magnification. Two authors (B. Yang and A.M.
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El Nahas) blinded to the experimental code scored the 0.05). These caspase-3 subunits were diminished in the
NTN kidneys treated with B-D-FMK in acute (	61%severity of glomerular injury/sclerosis, tubular atrophy,
for both, P  0.05) and chronic (	46% for 17 kD andand tubulointerstitial fibrosis, according to a previously
	37% for 24 kD, P  0.05) experiments. The 32 kDpublished arbitrary scale (from 0 to 3) [41]. Scores were
band, precursor of caspase-3, increased by 392% (P attributed as following: a normal glomerulus scored 0;
0.05) only in the chronically untreated NTN kidneys,mild glomerular sclerosis affecting up to 25% of glomer-
which was reduced by	38% (P 0.01) after B-D-FMKular tuft scored 1; moderate glomerular sclerosis affect-
treatment. The 29 kD processing intermediate was alsoing between 25% and 50% of tuft scored 2; and severe
present in the kidneys of all groups (Fig. 1B).glomerular sclerosis affecting in excess of 50% of tuft
We performed Northern blot analysis on kidney tis-scored 3. Tubulointerstitial scarring was defined and scored
sues to address whether B-D-FMK affected caspase-3as normal tubules with tubular cell number (TCN) ap-
transcription. In the acute group, the 2.7 kb caspase-3proximately 1000 and no expansion of interstitium scored
mRNA transcript (Fig. 1C) was increased by 250% in0; mild tubular atrophy with TCN approximately 800
the untreated NTN kidneys in comparison to controls,and interstitial edema or fibrosis (IF) affecting up to
which was further increased by 139% in the NTN kid-25% of the field scored 1; moderate tubular atrophy with
neys treated with B-D-FMK (P  0.05). In the chronic
TCN approximately 600 and IF affecting 25% to 50% study, caspase-3 mRNA was increased by 566% in the
of the field scored 2; and severe tubular atrophy with untreated NTN kidneys, but decreased by 	52% (P 
TCN approximately 400, IF exceeding 50% of the field 0.01) in the NTN kidneys treated with B-D-FMK (P 
scored 3. The data were collected from a series of adja- 0.05) (Fig. 1C).
cent fields extending perpendicularly from the cortex
toward the outer medulla. Three such randomly selected Effect of B-D-FMK on caspase-1 activity and proteins
linear series of minimum12 fields were measured in the There was no significant change in renal caspase-1
cortex or such number of fields until 30 glomeruli had activity (pmol AMC liberated per minute per g protein
been counted per section. at 30C) between experimental groups (Fig. 2A). Of
note, the competitive tetrapeptide inhibitor, Ac-YVAD-
Statistical analysis CHO, inhibited the activity of caspase-1 only about
Results are expressed as mean 
 standard error of 65.5% in the in vitro assay.
the mean (SEM). The statistical difference was assessed The expression of caspase-1 proteins was detected by
Western blotting analysis. The active subunit of caspase-1,by a single factor variance (ANOVA) or Student t test.
a 20 kD band, remained unchanged through both theP  0.05 was considered to be significant.
acute and chronic time courses and was not affected by
B-D-FMK (Fig. 2B). However, the precursor of caspase-1,
RESULTS a 45 kD band, was significantly decreased by 	40% in
Effect of B-D-FMK on caspase-3 activity, proteins, chronic NTN kidneys and increased again by18% after
and mRNA the treatment with B-D-FMK (P  0.05) (Fig. 2B).
Caspase-3 activity (pmol AMC liberated per minute B-D-FMK reduced IL-1 proteins and synthesis in
perg protein at 30C) was increased in the early (0.059
 NTN kidneys
0.005) and late (0.084
 0.009) untreated (DMSO/vehicle-
Although no significant changes in caspase-1 activityinfused) NTN kidneys compared to their controls (0.021

and the active subunit of caspase-1 were seen, the expres-0.004 and 0.027 
 0.005, respectively, P  0.01). This
sion of the caspase-1 precursor was reduced and cor-elevated caspase-3 activity was reduced in the NTN kid-
rected by B-D-FMK. Therefore, we further investigatedneys treated with B-D-FMK in both acute (	40%, P  whether B-D-FMK had an effect on IL-1 at both pro-
0.01) and chronic (	29%, P  0.05, Figure 1A) treat- tein and mRNA levels, as pro-IL-1 may be processed
ment groups. The specific and competitive tetrapeptide by either caspase-1, caspase-3 (caspase-1 independent),
inhibitor of caspase-3, Ac-DEVD-CHO, almost fully in- or both pathways [42].
hibited the caspase-3 activity in the assays, demonstra- IL-1 proteins in kidney tissues were determined by
ting the specificity of the assay. In the noncannulated Western blotting analysis. The 17 kD band representing
contralateral NTN kidneys, caspase-3 activity was also the IL-1 active subunit was increased in the acutely
significantly reduced to a similar level of the treated (223%) and chronically (169%) untreated NTN kid-
kidneys suggesting a systemic effect (data not shown). neys (P  0.05). This IL-1 subunit was reduced in the
Caspase-3 proteins in kidney tissues, determined by NTN kidneys treated with B-D-FMK of both groups,
Western blotting analysis, showed that 17 kD and 24 kD but did not reach statistical significance (	46% and
bands, representing caspase-3 active subunits, were in- 	42%, P  0.05). The 35 kD band, precursor of IL-1,
creased in the acutely (292% and 296%) and chroni- increased by 249% and 181% (P  0.05) in both
acutely and chronically untreated NTN kidneys, whichcally (361% and265%) untreated NTN kidneys (P
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Fig. 1. Caspase-3 activity, proteins and mRNA in kidney tissues. (A ) Caspase-3 activity assayed by the fluorometric substrate cleavage. Data
represents mean 
 SEM. (B ) Expression of caspase-3 proteins detected by Western blot analysis. Sample immunoblots of both acute and chronic
studies show 17 kD and 24 kD bands, representing the caspase-3–active subunits; a 32 kD band, representing the precursor of caspase-3; a 29 kD
band, representing processing intermediate of caspase-3. Histogram data represent the result of volume density analysis as mean percentage change
compared to the average of control values (mean 
 SEM). (C ) Tissue level of caspase-3 mRNA in rat kidneys assayed by Northern blot analysis.
Histogram shows volume density analysis of autoradiographs using cyclophilin corrected for loading. Data are expressed as mean percentage
change compared to the average of control values (mean 
 SEM). Abbreviations are: Cyc, cyclophilin (N  6 to 8); NS, normal serum; NTS,
nephrotoxic serum; DMSO, dimethyl sulfoxide; B-D-FMK, Boc-Asp (OMe)-fluoromethyl ketone; D7, B-D-FMK administration for 7 days; and
D28; B-D-FMK administration for 28 days. Symbols are: (), NS  DMSO; ( ), NTS  DMSO; and ( ), NTS  B-D-FMK. *P  0.05; **P  0.01.
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Fig. 2. Caspase-1 activity and proteins in kid-
ney tissues. (A ) Caspase-1 activity assayed by
the fluorometric substrate cleavage. Data rep-
resents mean 
 SEM. (B ) Expression of cas-
pase-1 proteins detected by Western blot anal-
ysis. Sample immunoblots of both acute and
chronic studies show 20 kD band, representing
the caspase-1 active subunit; a 45 kD band,
representing the precursor of caspase-1. His-
togram data represents the result of volume
density analysis as mean percentage change
compared to the average of control values
(mean 
 SEM) (N  6 to 8). Abbreviations
are: NS, normal serum; NTS, nephrotoxic se-
rum; DMSO, dimethyl sulfoxide; B-D-FMK,
Boc-Asp (OMe)-fluoromethyl ketone; Cyc,
cyclophilin; D7, B-D-FMK administration for
7 days; and D28; B-D-FMK administration for
28 days. Symbols are: (), NS  DMSO; ( ),
NTS  DMSO; and ( ), NTS  B-D-FMK.
*P  0.05; **P  0.01.
remained at a similar level in the acute group and was the chronic investigation, the expression of IL-1mRNA
was significantly increased by 270% in the untreatedreduced by 	66% (P  0.01) in the chronic group after
B-D-FMK treatment (Fig. 3A). NTN kidneys, which was subsequently decreased by
	59% in the NTN kidneys treated with B-D-FMK (P In the acute study, there was no significant change in
the expression of the 1.6 kb IL-1 mRNA (Fig. 3B). In 0.05, Fig. 3B).
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Fig. 3. Tissue level of interleukin-1 (IL-1)
proteins and mRNA. (A) Expression of IL-1
proteins detected by Western blot analysis.
Sample immunoblots of both acute and
chronic studies show 17 kD band, representing
the IL-1 active subunit; a 35 kD band, repre-
senting the precursor of IL-1. Histogram
data represents the result of volume density
analysis as mean percentage change compared
to the average of control values (mean 

SEM). (B ) Tissue level of IL-1 mRNA in
rat kidneys assayed by Northern blot analysis.
Histogram shows volume density analysis of
autoradiographs using cyclophilin (Cyc) cor-
rected for loading. Data is expressed as mean
percentage change compared to the average
of control values (mean
 SEM) (N 6 to 8).
Abbreviations are: NS, normal serum; NTS,
nephrotoxic serum; DMSO, dimethyl sulfox-
ide; B-D-FMK, Boc-Asp (OMe)-fluoromethyl
ketone; D7, B-D-FMK administration for 7
days; and D28, B-D-FMK administration for
28 days. Symbols are: (), NS  DMSO; ( ),
NTS  DMSO; and ( ), NTS  B-D-FMK.
*P  0.05; **P  0.01.
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Apoptotic changes following B-D-FMK administration Fibrotic and functional changes after
B-D-FMK treatmentApoptotic cells were detected by ISEL of fragmented
The extent of glomerular sclerosis, tubular atrophy,DNA. Positively stained cells were counted and con-
and tubulointerstitial fibrosis were semiquantitativelyfirmed by distinct morphologic motifs using light and
analyzed on the MT-stained sections. Glomerular sclero-electron microscopy. Very few apoptotic cells were noted
sis was severe and progressive in the untreated NTNin the glomeruli (0.012 
 0.009/glomerulus), tubules
kidneys (Fig. 7 a and e, acute; c and g, chronic). This(0.026
 0.008/400 tubular cells) and interstitium (0.057

was reduced by 	27% (Fig. 7 b and f, acute) and 	31%0.014/400 field) of control kidneys (Fig. 6A). In the
(Fig. 7 d and h, chronic) in NTN kidneys treated withacute study, apoptotic cells in glomeruli (0.467 
 0.073/
B-D-FMK for both time periods (Fig. 7i, P  0.05). Noglomerulus) were increased in untreated NTN kidneys
significant difference in tubular atrophy or tubulointers-
(Fig. 4a and a) compared with controls (P  0.01). This
tial fibrosis was noted in the early (acutely) untreated
was decreased by 	55% (P  0.01) in the NTN kidneys and treated NTN kidneys (Fig. 7 a, b, and i) compared
treated with B-D-FMK (Figs. 4b and 6A). In the chronic to controls (TCN, 960.0 
 8.2 tubular cell/200 field).
group, apoptotic cells in glomeruli were also higher in In the chronic study, tubular atrophy (TCN, 570.0
 31.3
untreated NTN kidneys (P 0.05), and were not affected tubular cell/200 field, P  0.01) and tubulointerstitial
by B-D-FMK treatment. Apoptotic cells in tubules fibrosis (Fig. 7 c, g, and i) were increased in the untreated
(1.112 
 0.238/400 tubular cells) and interstitium NTN kidneys compared to controls (TCN, 952.5 
 8.54
(0.680 
 0.072/400 field) were also increased in the tubular cell/200 field). Caspase inhibition significantly
untreated NTN kidneys (P  0.01, Fig. 4c); however, improved tubular atrophy (TCN, 714.00 
 39.32 tubular
this was significantly decreased by	64% (P 0.05) and cell/200 field, P  0.05) and reduced tubulointerstitial
fibrosis by 	34% (Fig. 7 d, h, and i).	57% (P 0.01), respectively, in the B-D-FMK–treated
These results were supported by the assay of tissueNTN kidneys (Fig. 4d and 6A). In both groups, the areas
collagen I, III, and IV mRNA using Northern blot analy-mostly contained apoptotic cells were the inflamed or
sis. In the acute study, the 4.8 kb/5.8 kb of collagen Isclerotic glomeruli (Fig. 4e) as well as the dilated or
mRNA was increased by 220% in the untreated NTNatrophied tubules (Fig. 4f) and expanded interstitium
kidneys, and further increased to 480% (P  0.05) in(Fig. 4g). Electron microscopy confirmed apoptotic cells
the NTN kidneys treated with B-D-FMK. There was nowith distinct morphological motifs in some glomeruli
significant change in the expression of 5.4 kb collagen(not shown), tubules (Fig. 4h) and interstitium (Fig. 4i).
III and 6.5 kb/4.5 kb collagen IV mRNA transcripts in
the acute study. In the chronic study, the expression ofInflammatory (ED-1) changes following B-D-FMK
collagen I, III and IV mRNAs increased by 1487%,administration in NTN kidneys
522% and 442% in the untreated NTN kidneys and
Inflammatory monocytic infiltration of the kidneys were decreased by 	63%, 	58% and 	72% in the
was evaluated by immunostaining of ED-1. A small num- treated kidneys (P  0.05, Fig. 7j to l).
ber of ED-1 cells were seen in the glomeruli (0.22 
 There was no detectable change in the body and kid-
0.01/glomerulus) and interstitium (1.02 
 0.12/400 ney weight or serum creatinine among groups in the
field) of control kidneys (Fig. 6B). Over the first 7 days, acute study (Table 1). In the chronic study, kidney weight
ED-1 cells were increased in the glomeruli (20.61 
 and serum creatinine, but not body weight, were signifi-
1.71/glomerulus) and interstitium (18.91 
 1.20/400 cant increased in the untreated rats. However, neither
was affected by B-D-FMK treatment (Table 1). Protein-field) of untreated NTN kidneys (P  0.01). This was
uria was significantly increased in both early and latedecreased by 	27% (P  0.01) in the glomeruli and by
untreated NTN rats (113.45
 13.18 and 399
 33.33 mg/	22% (P 0.05) in the interstitium following B-D-FMK
24 hours) compared to controls (P  0.01). Of note,treatment. In the chronic experiment, ED-1 cells in
NTN kidneys treated with B-D-FMK both acutelythe glomeruli (7.51 
 1.39/glomerulus) were less than in
(	38%) and chronically (	29%) had a significant reduc-the acutely untreated NTN kidneys but still significantly
tion of proteinuria (P  0.05, Table 1).higher than controls. No significant change was noted
after B-D-FMK treatment. In the interstitium of the late
untreated NTN kidneys, ED-1 cells (34.57
 3.15/400 DISCUSSION
field) were almost double that on the normal, but re- Apoptosis has a critical role in the resolution of in-
duced by 	53% (P 0.01) in those receiving B-D-FMK flammatory response, such as that occurring in glomeru-
treatment (Fig. 6B). Positive ED-1 cells were distributed lonephritis [2, 3]. However, if the induction of apoptosis
in the inflamed glomeruli (Fig. 5 a, b, e, and f), intersti- becomes uncontrolled, it leads to glomerular and tubular
cell deletion, and glomerular sclerosis as well as tubulartium and tubular lumen (Fig. 5 c, d, g, and h).
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Fig. 4. Renal cell apoptosis detected by in situ end-labeling (ISEL) the fragmented DNA. Apoptotic cells (indicated by arrows) are shown in
glomeruli (a, b, and e ), tubules (c, d, and f ) and interstitium (g ) at 200 (a to d) and 400 (e to g) magnification. Typical morphologic changes
of apoptosis such as a shrunken cell with condensed nuclei surrounded by narrow cytoplasmic halo is shown in an enlarged picture of a glomerular
apoptotic cell (a). Using electron microscopy, apoptotic cell phagocytosed by tubular cell (h, 6858) and apoptotic cell in interstitium are shown
(i, 6858).

atrophy and interstitial fibrosis subsequently ensued in caspase-3 activity in the infused and contralateral kid-
neys of both acute and chronic experimental groups. This[5, 7]. In previous experiments on rats with NTN and
SNx, we have observed the progressive glomerular and indicated that the local delivery of B-D-FMK for 7 or
28 days had a systemic effect. It also led to a decreasetubular cell apoptosis and postulated that renal cellular
apoptosis contributed to glomerulosclerosis and tubular of caspase-3 protein levels in renal tissues. More interest-
ingly, this decrease was despite an early up-regulationatrophy [7, 28]. In these studies, a strong association
was noted between the up-regulation of caspase-3, the of caspase-3 transcription as a compensatory reaction to
the inhibition of this enzyme, which declined later in theoccurrence of apoptosis, and the progression of scarring/
fibrosis [7, 29]. Recent evidence linking caspase-3 and experimental time course. These changes may reflect the
effect of autoadjustment to the caspase enzyme inhibitorinflammation indicates that caspase-3 may also play a
role in the inflammatory changes that characterize early at mRNA level in this in vivo model. All these results
indicate that the caspase-3 activity, proteins, and mRNAglomerulonephritis, as well as the late interstitial in-
flammation, which precedes renal fibrosis in progressive were affected by B-D-FMK. In other words, the action
of B-D-FMK on apoptosis and inflammation during theglomerulonephritis [7, 25]. The pivotal role of caspase-
3 in the machinery of apoptosis and inflammation makes course of NTN may be predominantly through the inhibi-
tion of caspase-3.it as an attractive target to regulate the progression of
glomerulonephritis and renal fibrosis. Posttranslation, caspase-3 can be activated through
three pathways. First, caspase-3 activation may be medi-In this study, we have used the intrarenal administration
of a cell-permeable pan caspase inhibitor, B-D-FMK, to ated by death receptors, such as (Fas/FasL system),
which is associated with the activation of caspase-8. Sec-test the effect of caspase inhibition on both apoptosis
and inflammation, and the ensuing renal scarring in the ond, caspase-3 activation may also be mediated by the
mitochondria (through Bax/Bcl-2) with release of cyto-in vivo rat NTN model. The administration of B-D-FMK
in the acute phase (starting 1 day before NTN and lasting chrome c, which is required for caspase-9 activation [10,
44, 45]. Third, caspase-3 can be activated by caspase-127 days) of NTN prevented the early onset of glomerular
apoptosis and inflammation. In addition, the early inhibi- when the ER is under stress [12]. Auto- or transactivation
of initiator caspase-8, caspase-9, and caspase-12 resultstion of caspase also blunted tubulointerstitial inflamma-
tion. These effects may have contributed to the attenua- in the subsequent cleavage and activation of the down-
stream effector caspase-3 [10]. B-D-FMK is a pan cas-tion of glomerular injury and proteinuria. Conversely,
when B-D-FMK was administered chronically starting pase inhibitor and was assumed to have a role on all
caspases, including caspase-8, caspase-9, and caspase-12.on day 15 after the induction of NTN and continuing
for 28 days, it predominantly ameliorated the tubular Therefore, B-D-FMK not only directly inhibited the ac-
tivity of caspase-3 (demonstrated by the caspase-3 activ-apoptosis, interstitial inflammation, and fibrosis. It also
reduced glomerulosclerosis and proteinuria. These re- ity assay), but also prevented the formation of active
caspase-3 (showed by the expression of caspase-3 pro-sults indicate that this pan caspase inhibitor has a poten-
tial not only to prevent, but also to halt, the progression teins) by possibly causing a reduction in the activity of
caspase-8, caspase-9, or caspase-12. So the effects ofof glomerulosclerosis and interstitial fibrosis [43].
In order to evaluate the protective mechanisms of B-D-FMK on apoptosis and inflammation may be attrib-
uted to the inhibition of both caspase-3 activity and acti-B-D-FMK in renal injury, we detected the expression of
caspase-3 at activity, protein and mRNA levels in renal vation. Further, we cannot rule out a role for B-D-FMK
on other caspases, such as caspase-6 and caspase-7 (an-tissues. Caspase-3 is a key enzyme in the apoptotic pro-
cess and is also involved in the progression of inflamma- other two effector caspases), which could be the subject
of future studies.tion [11, 25]. Application of B-D-FMK led to a decrease

Fig. 5. Renal Inflammation evaluated by ED1 staining. ED1 cells in glomeruli (a, b, e, and f ) and interstitium (c, d, g, and h ) at 100 (a to d)
and 200 (e to h) magnification.
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Fig. 6. Histograms show semi-quantitative
analysis of both renal apoptosis (A ) and in-
flammation (B ). Data represents mean 

SEM (N  6 to 8). Abbreviations are: NS,
normal serum; NTS, nephrotoxic serum;
DMSO, dimethyl sulfoxide; B-D-FMK, Boc-
Asp (OMe)-fluoromethyl ketone; Gapo, apo-
ptotic cells per glomerulus; Tapo, apoptotic
cells per 400 tubular cells; Iapo, apoptotic cells
per 400 field; Ged1, ED1 staining cells
per glomerulus; Ied1, ED1 staining cells per
400 field; D7, B-D-FMK administration for
7 days; and D28; B-D-FMK administration for
28 days. Symbols are: (), NS  DMSO; ( ),
NTS  DMSO; and ( ), NTS  B-D-FMK.
*P  0.05; **P  0.01.
The appearance of apoptosis is closely correlated with could happen when the apoptotic inflammatory cells did
not be cleared away in time. While initial reports dissoci-the increase of caspase-3 activity, as shown in our previ-
ous study in this experimental model of accelerated glo- ated apoptosis from inflammation, a growing body of
experimental evidence links the two, which was clearlymerulonephritis [7]. In the present investigation, B-D-FMK
with caspase-3 inhibition decreased the occurrence of demonstrated following renal ischemia/reperfusion in-
jury [25]. On the other hand, we have expected that theapoptosis as revealed by the decreased number of ISEL-
positive nuclei. The inhibition of apoptosis occurred inhibition of apoptosis in the acute phase of glomerulo-
nephritis would have led to diminish the resolution ofearly in the glomeruli mainly after an acute administra-
tion of B-D-FMK for 7 days and late predominantly in acute glomerulonephritis contributing to further scar-
ring. However, we failed to observe such a deleteriousthe tubulointerstitium after chronic treatment for 28 days.
The inhibition of early apoptosis in the glomeruli may effect in our acute experiment, which may be hidden
by the direct effect of B-D-FMK on inflammation. Inlead to the reduction of secondary inflammation that
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Fig. 7. Renal fibrosis analyzed on Masson’s Trichrome–stained sections and by collagen I, III, and IV mRNAs. Glomerular injury and sclerosis
and tubulointerstitial fibrosis in Masson’s Trichrome–stained sections at 200 (A to D ) and 400 (E to H ) magnification. Histogram (I ) shows
semiquantitative analysis of renal fibrosis. Data represents mean 
 SEM. Tissue levels of collagen I (J ), III (K ), and IV (L ) mRNAs in rat kidneys
assayed by Northern blot analysis. Histogram shows volume density analysis of autoradiographs using cyclophilin (Cyc) corrected for loading.
Data is expressed as mean percentage change compared to the average control value (mean 
 SEM) (N  6 to 8). Abbreviations are: NS, normal
serum; NTS, nephrotoxic serum; DMSO, dimethyl sulfoxide; B-D-FMK, Boc-Asp (OMe)-fluoromethyl ketone; D7, B-D-FMK administration for
7 days; and D28; B-D-FMK administration for 28 days. Symbols are: (), NS  DMSO; ( ), NTS  DMSO; and ( ), NTS  B-D-FMK. *P 
0.05; **P  0.01.
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Table 1. Changes of body weight, kidney weight, serum creatinine, and proteinuria in nephrotoxic nephritis (NTN) rats following Boc-Asp
(OMe)-fluoro-methyl-ketone (B-D-FMK) treatment.
B-D-FMK 7 days NTN 6 days NTN 43 days B-D-FMK 28 days
Parameters NS  DMSO NTS  DMSO NTS  B-D-FMK NS  DMSO NTS  DMSO NTS  B-D-FMK
Body weight g 306.0
10.0 295.0
1.5 317.4
7.1 324.5
12.1 329.4
4.3 326.1
4.7
Kidney weight g 1.03
0.05 1.08
0.04 1.14
0.03 0.95
0.03 1.37
0.06a 1.26
0.07
Serum creatinine lmol/L 37.5
4.1 39.4
2.3 42.6
2.4 43.8
2.0 73.7
5.4a 79.3
10.0
Proteinuria mg/24 hours 42.9
4.3 113.5
13.2a 69.8
11.1b 67.0
20.3 399.1
33.3a 282.1
43.2b
Abbreviations are: NS, normal serum; NTS, nephrotoxic serum; and DMSO, dimethylsulfoxide.
aP  0.01; bP  0.05
addition, the resolution of acute glomerulonephritis may flammation may provide a microenvironment that favors
the development of apoptosis. Apoptosis and inflamma-also depend on the migration of inflammatory cells out
of the glomeruli upon completion of their task [46]. tion may share so far-unknown upstream molecular me-
diating mechanisms.The caspase inhibition by B-D-FMK may have had a
direct effect on inflammation. There was a reduction of As we demonstrated previously, renal apoptosis and
inflammation are associated with tubular atrophy andED-1 cells early in the glomeruli and tubulointerstit-
ium, and late in the tubulointerstitium. This may result renal fibrosis [7, 29]. It has been revealed that the swift
uptake and degradation of apoptotic cells by phagocytesfrom the reduction of apoptosis as we postulated above.
In addition, the decrease of inflammatory cell infiltration leads to a very short half-life for apoptotic cells [3]. Thus,
the changes in the small numbers of detectable apoptoticmay be linked to the reduction of inflammatory media-
tors such as IL-1. B-D-FMK is a broad-spectrum inhibi- cells may mask a higher rate of apoptosis and result in a
significant loss of renal cell mass. Therefore, the inhibitiontor of activated caspases, including not only caspase-3 but
also caspase-1. Apart from a functional role on apoptosis of renal cell apoptosis and inflammation, in particular,
late tubular cell apoptosis and interstitial inflammation,[47], caspase-1, also referred to as ICE, is associated
with the activation of IL-1. However, we did not show by B-D-FMK could be helpful to preserve renal paren-
chymal cells and renal function. The reduction in apopto-a significant change in caspase-1 activity and its active
protein in our study, but the precursor of caspase-1 was sis and inflammation was associated with the improve-
ment of proteinuria and renal morphology, includingdecreased in chronic NTN kidneys and increased again
after treatment with B-D-FMK. These may reveal that glomerular sclerosis, tubular atrophy, and tubulointersti-
tial fibrosis. The reduction in interstitial fibrosis was sup-there was a continuous activation and consumption of
caspase-1 simultaneously during time course, which ported by the reduction of collagen I, III, and IV mRNA
expression in the chronic study group. There was a statis-would have led to a continuous cleavage of the caspase-1
precursor and kept a stable overall level of active cas- tically significant improvement in renal cellular apoptosis,
inflammation, and fibrosis with both acute and chronicpase-1 in the NTN kidneys. This continuous consumption
of active caspase-1 may have been involved in the pro- administration of the pan caspase inhibitor. However,
we are aware that there is variation between animalscessing of IL-1. Furthermore, IL-1 active and precur-
sor subunits were significantly increased in both groups and that this kind of treatment partially halted but did
not completely stop the progression of renal scarring.of untreated NTN kidneys and reduced by B-D-FMK
treatment, although this only reached significance in the Further, we failed to observe a satisfactory improvement
in serum creatinine level. Although we did not noticechronic groups. These data found are also consistent
with the changes observed in the IL-1 mRNA levels. an obvious toxicity in liver and heart tissues (on hema-
toxylin and eosin sections, data not shown), the systemicIt suggests that the changes of IL-1 protein (both active
and precursor subunits) and mRNA can occur through toxicity of B-D-FMK needs further investigation. Ad-
justment in the dose of B-D-FMK may be required tothe activation of caspase-1 [42]. IL-1 could in turn con-
tribute to renal inflammation and scarring. Nevertheless, maximize its protective effects and the delivery method
needs to be improved to avoid the damage caused bythese processes can be inhibited by a pan caspase inhibi-
tor in vivo. In addition, the processing of other inflam- the intrarenal cannulation, although this was contrasted
by the vehicle administration to the control animals.matory mediators, such as IL-18 and macrophage inflam-
matory protein-2 (MIP-2), may require the activation of Apart from caspase, there are another two groups of
cysteine proteases, the cathepsin and calpain [50]. Al-caspase-3 [48, 49]. Apoptosis and inflammation could be
mutually affected. This was highlighted by the inhibition though cathepsins do not appear to play a role in lethal cell
injury, calpain plays an injurious role in ischemic injury toof apoptosis using by ZVAD-FMK and insulin-like
growth factor-1 (IGF-1) in renal ischemia/reperfusion, liver, heart, brain and renal ischemia/reperfusion [50, 51].
Calpain activation has been associated with the down-which prevented the associated inflammation [25]. In-
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